231 related articles for article (PubMed ID: 21670382)
1. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
[TBL] [Abstract][Full Text] [Related]
3. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Goldstein LB; Amarenco P; Lamonte M; Gilbert S; Messig M; Callahan A; Hennerici M; Sillesen H; Welch KM;
Stroke; 2008 Sep; 39(9):2444-8. PubMed ID: 18617654
[TBL] [Abstract][Full Text] [Related]
4. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Chaturvedi S; Zivin J; Breazna A; Amarenco P; Callahan A; Goldstein LB; Hennerici M; Sillesen H; Rudolph A; Welch MA;
Neurology; 2009 Feb; 72(8):688-94. PubMed ID: 18768917
[TBL] [Abstract][Full Text] [Related]
5. High-dose atorvastatin after stroke or transient ischemic attack.
Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin: its clinical role in cerebrovascular prevention.
Gaspardone A; Arca M
Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: translating evidence on statin therapy into clinical benefits.
Sanossian N; Ovbiagele B
Nat Clin Pract Neurol; 2008 Jan; 4(1):43-9. PubMed ID: 18199996
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Arca M
Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
[TBL] [Abstract][Full Text] [Related]
11. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
Amarenco P; Bogousslavsky J; Callahan AS; Goldstein L; Hennerici M; Sillsen H; Welch MA; Zivin J;
Cerebrovasc Dis; 2003; 16(4):389-95. PubMed ID: 14584489
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Knopp RH; d'Emden M; Smilde JG; Pocock SJ
Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin in prevention of stroke and transient ischaemic attack.
Amarenco P
Expert Opin Pharmacother; 2007 Nov; 8(16):2789-97. PubMed ID: 17956199
[TBL] [Abstract][Full Text] [Related]
14. Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Fitchett DH; Goodman SG; Langer A
Can J Cardiol; 2008 Sep; 24(9):705-8. PubMed ID: 18787721
[TBL] [Abstract][Full Text] [Related]
15. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
[TBL] [Abstract][Full Text] [Related]
16. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Szarek M; Sillesen H; Rudolph AE; Callahan A; Hennerici M; Simunovic L; Zivin JA; Welch KM;
Stroke; 2007 Dec; 38(12):3198-204. PubMed ID: 17962589
[TBL] [Abstract][Full Text] [Related]
17. Expanding roles for atorvastatin.
Singh V; Deedwania P
Drugs Today (Barc); 2008 Jun; 44(6):455-71. PubMed ID: 18596999
[TBL] [Abstract][Full Text] [Related]
18. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
[TBL] [Abstract][Full Text] [Related]
19. SPARCL: the glimmer of statins for stroke risk reduction.
Armani A; Toth PP
Curr Atheroscler Rep; 2007 Nov; 9(5):347-51. PubMed ID: 18001616
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.
Athyros VG; Kakafika AI; Papageorgiou AA; Tziomalos K; Skaperdas A; Pagourelias E; Pirpasopoulou A; Karagiannis A; Mikhailidis DP;
Lipids; 2007 Nov; 42(11):999-1009. PubMed ID: 17713803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
